Sareum Holdings PLC’s (LON:SAR) latest drug candidate has the potential to fight a number of cancers, according to a poster presentation given on Tuesday in the US by the firm’s chief executive, Dr Tim Mitchell.
He said there was a “good level of interest directed” at the company’s discovery from delegates at the American Association for Cancer Research’s annual gathering.
“The conference is an important international cancer congress showcasing innovative research from academic and pharmaceutical organisations from around the world,” the Sareum CEO added.
The presentation noted that in lab models, SDC-1802, a TYK2/JAK1 inhibitor, significantly reduced tumour growth in cancers of the pancreas, colon, skin and kidney, plus B-cell lymphoma.
The studies showed it induced anti-cancer activity through a new mechanism that stimulates the local immune system to attack rogue cells.
The drug was used on its own and in combination with the best treatment currently on the market for the various cancers studied.
Saruem said in an earlier release that it believes it has developed a “potentially powerful” immunotherapy that will help combat the killer diseases.
“There was a good level of interest directed at novel immunotherapy mechanisms such as TYK2/JAK1 inhibition and we look forward to further discussions with interested parties," said CEO Mitchell.